XOMA News and Press, XOMA Corporation From 12/29/23

2023-12-29 07:00:00 ET Summary XOMA Corporation specializes in financing new drug development and offers preferred stocks as investment options. XOMA's strategy involves acquiring economic rights to future milestones and royalty payments associated with partnered pre-commercial cl...

Low-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO ® (faricimab) royalties in 2021 Proceeds expected to be used for stock repurchases and additional royalty and milestone acquisitions Financing from Blue Owl extends XOMA’s capabi...

2023-12-15 08:30:00 ET Summary Preferred shares present a desirable trifecta of high yields, lower risk, and significant capital upside. At these bargain prices, preferred stocks have something for value, income, and growth investors. We discuss two +9% yielding preferreds for...

2023-11-07 07:58:51 ET More on XOMA XOMA Corporation: Playing The Drug Royalty Strategy Via Preferreds XOMA gets $5M milestone upon FDA's acceptance of Day One's Tovorafenib NDA Novartis ending development of pancreatic cancer asset licensed from XOMA Seeking...

Received $6.6 million in cash receipts during the quarter related to our growing royalty base and certain development milestones One New Drug Application (NDA) was filed in the third quarter; another is anticipated prior to year-end Company anticipates the initiation of multiple...

XOMA Corporation (XOMA) is expected to report $-0.48 for Q3 2023

EMERYVILLE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $5 million milestone related to the U.S. Food and Drug Administration’s (FDA) acceptance of Day One Biopharmaceuticals’ New Drug App...

2023-10-06 07:35:00 ET Summary Charlie Munger passively made a fortune with his $1,000 oil royalty investment in 1962. Royalty interests are an unstoppable force for inflation-beating passive income. Each royalty firm has a unique treasure chest waiting to be unlocked. Joi...

2023-10-05 10:46:01 ET More on XOMA Novartis ends development of pancreatic cancer asset licensed from XOMA XOMA Corporation: Playing The Drug Royalty Strategy Via Preferreds For further details see: XOMA says chief investment officer Sitko buys 1.75K shares

EMERYVILLE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, will present a company update at the H.C. Wainwright 25 th Annual Global Investment Conference on Tuesday, September 12, 202...